| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ABBV | Common Stock, $0.01 par value | Options Exercise | $867,630 | +14,140 | +52% | $61.36 | 41,205 | 23 Feb 2024 | Direct | |
| transaction | ABBV | Common Stock, $0.01 par value | Sale | $2,509,002 | -14,140 | -34% | $177.44 | 27,065 | 23 Feb 2024 | Direct | F1 |
| transaction | ABBV | Common Stock, $0.01 par value | Tax liability | $2,082,370 | -11,634 | -43% | $178.99 | 15,431 | 28 Feb 2024 | Direct |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ABBV | Option (Right to buy) | Options Exercise | $867,630 | -14,140 | -45% | $61.36 | 17,380 | 23 Feb 2024 | Common Stock | 14,140 | $61.36 | Direct | F2 |
| Id | Content |
|---|---|
| F1 | The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.41 to $177.55, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F2 | Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. |